Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nichi-Iko Reveals Possible Supply Delays for 164 Products, Stirs Confusion at Peers, Customers
April 23, 2021
- Chugai’s Q1 Sales Slide 5.9% on Drug Price Cuts, Gx, Frontloaded Actemra Exports
April 23, 2021
- Stella Pharma Goes Public on TSE
April 23, 2021
- Mitsubishi Tanabe Files Tardive Dyskinesia Drug in Japan
April 23, 2021
- Chugai Eyes Japan Submission for COVID-19 Antibody Cocktail by Year-End
April 23, 2021
- Takeda Teams Up with IT Startup for AI-Driven Early HAE Detection
April 23, 2021
- Kobayashi Kako Starts Recalling Products Subject to Approval Revocation
April 22, 2021
- Calquence, Adlumiz, Zymso Now Available in Japan
April 22, 2021
- Supply Delays Likely for 160 Nichi-Iko Products despite Biz Suspension Lifted
April 22, 2021
- Fujifilm Launches New Japanese Avigan PIII Study for COVID-19
April 22, 2021
- MSD Japan Suffers 7% Sales Dip on Repeated Keytruda Re-Pricing, Urges Policy Rethink
April 21, 2021
- FDA Accepts Astellas/Seagen’s Submissions for Padcev’s Full Approval, Label Expansion
April 21, 2021
- Oncolys to Codevelop COVID-19 Med with Shin Nippon Biomedical
April 21, 2021
- Life Science Institute to Begin Exploratory Study of Muse Cell Therapy for COVID-19-Associated ARDS
April 21, 2021
- New Grad Hiring Down 3.3% at 55 Drug Makers, Sales Rep Opportunities Fall amid DX: Survey
April 20, 2021
- Bayer’s Japan Sales Sag 5%, but Targets Reached in 2020
April 19, 2021
- Kobayashi Kako Chief Sorry for Fake Application Documents; Third-Party Report Reveals New Problems
April 19, 2021
- Takeda, Nihon Pharm to Discuss Integration of Plasma Businesses
April 19, 2021
- Fujifilm Holdings Aims to Ring Up Healthcare Sales of 860 Billion Yen in FY2023: 3-Year Biz Plan
April 19, 2021
- High Court Backs Positive Ruling for Shionogi in Osaka Tax Suit
April 16, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…